- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00741754
Evaluation of the Unstimulated Whole Saliva Flow During and After Radiotherapy, With the Use HcT20 (EUWSFDAR)
March 30, 2009 updated by: UPECLIN HC FM Botucatu Unesp
Evaluation of the Unstimulated Whole Saliva Flow During and After Radiotherapy, With the Use of Lauryl-Diethylene-Glycol-Ether Sodium Sulfate Associated With Calcium Hydroxide (hCt20).
The aim of this report was to evaluate the unstimulated whole saliva flow in patients with head and neck cancers during and after the exclusive radiotherapy with an association of lauryl-diethylene-glycol-ether sodium sulfate and calcium hydroxide (Hct20).
This study was held at the buccal cancer center of UNESP and involved thirty one patients (n = 31) divided into two groups: Group 1 had seventeen patients (n = 17) submitted to fractioned radiation treatment in the head and neck region at the total dose of 7.000 cGy and had Hct20 during the treatment.
Group 2 with fourteen patients (n = 14) started with the use of Hct20 after the end of radiotherapy.
A weekly and measured collection of the index of the total non stimulated saliva flow was done on the patients of both groups.
The values that were obtained were analyzed statistically through the Bartlett test, the Friedman test and the Wilcox test, to seek an evaluation of effectiveness of the medication on the prevention of the intense drop of the salivary flow during the radiotherapy and do avoid the xerostomia during the post-radiotherapeutic period.
The patients from group 1 at the end of the radiotherapy kept the base index of the total non stimulated salivary flow, the ones from group 2 that used the medication association after the radiotherapy had a great improvement of total non stimulated salivary flow and the usage of the Hct20 had a better result on the index of salivary flow during the radiotherapy.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Thirty one patient were observed and treated at Oral Cancer Center - Brazil, between March 1997 and June 2006, distributed into two groups the following way: Group I composed of seventeen patients who utilized Hct20 during the period of the radiotherapy and Group II composed of fourteen patients who utilized the drug association from the radiotherapeutic treatment.
The average of the patients in group I was of 58.8 and Group II 64.7 years old.
In the distribution, as to sex, group I was composed by fourteen males and three females and in group II 11 male and four female.As to their color, group I presented sixteen white patients and one non-white and group II presented 12 white and two non-white.
From the patients in group I, eight referred elitism, six reported social elitism and three denied it; from the patients in group II five referred elitism, two reported social elitism and seven denied it.
All the patients, in both groups, presented lesions with primary site in the mouth, oropharynx or larynx with diagnosis of squamous cell carcinoma.
The patients included in this research were carriers of oral and oropharynx squamous cell carcinoma guided for exclusive radiotherapeutic treatment.To be accepted in this study, it was established as a requirement that the fields of irradiation included in all occasions the major salivary glands, partially or totally.Patients who used medical drugs wich could interfere in the salivary flow rate, with teeth, mucositis or any other alteration of the oral mucosa after radiotherapy was excluded.Group I was composed of seventeen patients (n=17)that performed eight saliva collection, being one before the treatment (c0) and seven collection (C1to C7) during seven weeks of radiotherapy utilizing Hct20.Group II was composed of fourteen patients (n=14) Who performed nine collections, being one collection (C7) at the end of the treatment without utilizing Hct20, six collections (c8 to C13) utilizing Hct20 the first two months after radiotherapy and two collections (C14 and C15) with three and four months after radiotherapy and after suspending the use of Hct20.The total dose administered to the patients was of 7000 cGy, fractioned in doses of 200 cGy daily, with Five fractions weekly.
The composition of Hct20 is 800 ml distilled water, 200 ml of lauryl-diethylene-glycol-ether sodium sulfate (0.125 g/ml) and 2 g of calcium hydroxide.The patients received a vial containing Hct20 and were oriented to perform two oral rinses daily with 10 ml.The collections of unstimulated whole saliva were weekly performed always in the same day of the week, around the same time, before breakfast, without oral hygienization, in the same office with the same illumination and silence and without the presence of companies in the period of the patient in the office.The patients expelled the unstimulated salivary secretion in a test tube calibrated in cubic millimeters with a funnel of eight centimeters of diameter adapted to it.At the end of the collections, wich lasted five minutes, were added three ml of distilled water to each sample, which was stored in a temperature of 6 degree Celsius for 24 hours in order to decrease the bubbles and the foams of the samples.
The three ml added to the end of the collection were despised at the moment of the final reading.The values that were obtained were analyzed statistically through the Bartlett test, the Friedman test and the Wilcox test, to seek an evaluation of effectiveness of the medication on the prevention of the intense drop of the salivary flow during the radiotherapy and do avoid the xerostomia during the post-radiotherapeutic period.
The patients from group 1 at the end of the radiotherapy kept the base index of the total non stimulated salivary flow, the ones from group 2 that used the medication association after the radiotherapy had a great improvement of total non stimulated salivary flow and the usage of the Hct20 had a better result on the index of salivary flow during the radiotherapy.
Study Type
Interventional
Enrollment (Actual)
31
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
São Paulo
-
Araçatuba, São Paulo, Brazil, 16015-050
- Dental School - São Paulo State University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years to 82 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- presented lesions with primary site in the mouth, oropharynx or larynx with diagnosis of squamous cell carcinoma.
- the patients were edentulous
- The patients included were guided for exclusive radiotherapeutic treatment.
- To be accepted in this study, it was established as a requirement that the fields of irradiation included in all occasions the major salivary glands, partially or totally.
Exclusion Criteria:
- Patients who used medical drugs wich could interfere in the salivary flow rate, with teeth, mucositis or any other alteration of the oral mucosa after radiotherapy was excluded.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: I, II
compare the amount of salivary flow of the same patient at different times.
|
Mouthrinse for 1 minute with 10ml, twice a day.
During seven weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
unstimulated whole saliva flow
Time Frame: ml
|
ml
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Éder Ricardo Biasoli, DdS, MsC, PhD. Professor of Oral Diagnosis, School of Dentistry, São Paulo State University - UNESP - Araçatuba - SP - Brazil.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2005
Primary Completion (Actual)
May 1, 2006
Study Completion (Actual)
July 1, 2006
Study Registration Dates
First Submitted
August 25, 2008
First Submitted That Met QC Criteria
August 25, 2008
First Posted (Estimate)
August 26, 2008
Study Record Updates
Last Update Posted (Estimate)
April 1, 2009
Last Update Submitted That Met QC Criteria
March 30, 2009
Last Verified
August 1, 2008
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- upeclin/FOA-Unesp-01
- COB-FOA-Unesp-chrishct20
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Abnormalities, Radiation-Induced
-
State University of New York - Upstate Medical...Carol M. Baldwin Breast Cancer Research Fund, Inc.TerminatedAbnormalities, Radiation-InducedUnited States
-
Korea Institute of Radiological & Medical SciencesActive, not recruitingRadiation Effects | Neoplasms, Radiation-Induced | Occupational Exposure to Radiation | Leukemia, Radiation-InducedKorea, Republic of
-
National Cancer Institute (NCI)CompletedRadiation-Induced Neoplasms | Breast+Neoplasm+Radiation+Etiology | Thyroid+Neoplasm+Radiation+EtiologyUnited States
-
University Health Network, TorontoCompletedAbnormalities, Radiation-InducedCanada
-
McMaster UniversityNot yet recruitingOxidative Stress | Radiation Exposure | DNA Damage, Radiation Induced
-
Apeiron BiologicsCompleted
-
University Medical Center GroningenCompletedRadiation Induced Cardiac DamageNetherlands
-
Pharm Olam Pharmaceuticals Ltd.UnknownPrevention of Radiation Induced Dermatitis.
-
Assistance Publique - Hôpitaux de ParisCompletedRadiation Induced Brachial PlexopathyFrance
-
Chang Gung Memorial HospitalNot yet recruiting
Clinical Trials on Mouthrinse with HcT20
-
Johnson & Johnson Consumer and Personal Products...Completed
-
InQpharm GroupCompletedDentin SensitivityGermany
-
Claude Bernard UniversityHospices Civils de LyonCompletedCOVID-19: Nasal and Salivary Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses (BBCovid)COVID19 | Saliva | MouthwashFrance
-
University of ChileFundación Debra ChileEnrolling by invitationOral Ulcer | Epidermolysis BullosaChile
-
Universiti Sains Islam MalaysiaCompletedPlaque Accumulation | Patient AcceptanceMalaysia
-
The University of Hong KongCompleted
-
Indiana Nanotech, LLCThe University of Texas Health Science Center at San AntonioCompleted
-
GlaxoSmithKlineCompleted
-
University of OsloUnknown
-
Johnson & Johnson Consumer Inc. (J&JCI)CompletedGingivitis | PlaqueUnited States